BioSpace News Archive

Award Recognizes Exceptional Contributions by Women in the Life Sciences Industry

Humacyte, Inc. will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024.

Checkpoint Therapeutics, Inc. today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.

Exagen Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.

Indaptus Therapeutics, Inc. announces that its CEO, Jeffrey Meckler, will present and participate in an open Q&A on Tribe Public’s Webinar titled, “Fully Engaging The Human Immune System To Cure Disease.”

Spyre Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses.

Bio-Thera Solutions announced today a new licensing agreement for two biosimilars under which SteinCares will have exclusive rights to distribute and market Bio-Thera’s pharmaceuticals in Brazil and the rest of the region.

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc.

Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin”).

NANO-X IMAGING LTD today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.